TOKYO–(BUSINESS WIRE)–Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter �Solasia) officially announced today that an organoarsenic drug DARVIAS® Injection 135mg (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).
Solasia Pharma K.K.
Toyokazu Ohata, Public Relations and Investor Relations
Tel: +81 3 5843 8046 (TOKYO)
info@solasia.co.jp
HONG KONG SAR - Media OutReach Newswire - 22 November 2024 - Minsuzenraku, Taiwan's highly…
Bringing together UK and global expertise, the 12th edition of the global language testing and…
SINGAPORE - Media OutReach Newswire - 22 November 2024 - Wine enthusiasts in Singapore can…
HONG KONG SAR - Media OutReach Newswire - 22 November 2024 - The spirit of…
The Press Conference for the Event Was Held This Afternoon at the Galaxy International Convention…
HONG KONG SAR - Media OutReach Newswire - 22 November 2024 - The Hong Kong…